Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Puig

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Bone Marrow Transplantation|September 26, 2019
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantationT Caballero-Velázquez, C Calderón-Cabrera, L López-Corral, et al.
Blood Cancer Journal|August 26, 2017
From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformationC Jiménez, S Alonso-Álvarez, M Alcoceba, et al.
Leukemia|May 3, 2016
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myelomaV González-Calle, J Dávila, F Escalante, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemiaR García-Sanz, Em Ocio, A Caballero, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 5, 2012
A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantationJ Lopez-Hellin, C Cantarell, L Jimeno, et al.
Leukemia|July 18, 2013
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometryN Puig, M E Sarasquete, A Balanzategui, et al.
Leukemia|November 4, 2017
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trialsP Arana, B Paiva, M-T Cedena, et al.
Blood Cancer Journal|November 21, 2018
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)L Sanoja-Flores, J Flores-Montero, J J Garcés, et al.
Blood Cancer Journal|April 29, 2024
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progressionA Medina-Herrera, I Vazquez, I Cuenca, et al.
Leukemia|August 2, 2016
Differentiation stage of myeloma plasma cells: biological and clinical significanceB Paiva, N Puig, M T Cedena, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Bone Marrow Transplantation|September 26, 2019
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantationT Caballero-Velázquez, C Calderón-Cabrera, L López-Corral, et al.
Blood Cancer Journal|August 26, 2017
From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformationC Jiménez, S Alonso-Álvarez, M Alcoceba, et al.
Leukemia|May 3, 2016
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myelomaV González-Calle, J Dávila, F Escalante, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemiaR García-Sanz, Em Ocio, A Caballero, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 5, 2012
A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantationJ Lopez-Hellin, C Cantarell, L Jimeno, et al.
Leukemia|July 18, 2013
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometryN Puig, M E Sarasquete, A Balanzategui, et al.
Leukemia|November 4, 2017
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trialsP Arana, B Paiva, M-T Cedena, et al.
Blood Cancer Journal|November 21, 2018
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)L Sanoja-Flores, J Flores-Montero, J J Garcés, et al.
Blood Cancer Journal|April 29, 2024
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progressionA Medina-Herrera, I Vazquez, I Cuenca, et al.
Leukemia|August 2, 2016
Differentiation stage of myeloma plasma cells: biological and clinical significanceB Paiva, N Puig, M T Cedena, et al.
Pageof 6